Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Itezocabtagene autoleucel by Tessa Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...
Itezocabtagene autoleucel by Tessa Therapeutics for Natural Killer Cell Lymphomas: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Natural Killer Cell Lymphomas. According...
Itezocabtagene autoleucel by Tessa Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...
Itezocabtagene autoleucel by Tessa Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData,...
Itezocabtagene autoleucel by Tessa Therapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According...
Itezocabtagene autoleucel by Tessa Therapeutics for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL)....
TT-11X by Tessa Therapeutics for Lymphoproliferative Disorders: Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Lymphoproliferative Disorders. According to GlobalData, Phase...
TT-11X by Tessa Therapeutics for Leiomyosarcoma: Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase I...
TT-11X by Tessa Therapeutics for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL). According...
TT-11X by Tessa Therapeutics for Nasopharyngeal Cancer: Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase...
TT-11X by Tessa Therapeutics for Natural Killer Cell Lymphomas: Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Natural Killer Cell Lymphomas. According to...
TT-11X by Tessa Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
TT-11X by Tessa Therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
Itezocabtagene autoleucel by Tessa Therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)....
TT-11X by Tessa Therapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to...
TT-16 by Tessa Therapeutics for Gastric Cancer: Likelihood of Approval
TT-16 is under clinical development by Tessa Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
TT-16 by Tessa Therapeutics for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
TT-16 is under clinical development by Tessa Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...